Background. Recent studies have indicated a stabilization in the incidence rates of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in a number of European countries. The aim of this study was to provide an update on the incidence, prevalence and outcomes of RRT in Europe over the past decade. Methods. Nineteen European national or regional renal registries with registry data from 1997 to 2006 participated in the study. Incidence and prevalence trends were analysed with Poisson and Joinpoint regression. Cox regression methods were used to examine patient survival. Results. The total adjusted incidence rate of RRT for ESRD increased from 109.9 per million population (pmp) in 1997 to 119.7 pmp in 2000, i.e. an average annual percentage change (AAPC) of 2.9% (95% CI 2.1-3.8%). Thereafter, the incidence increased at a much lower rate to 125.4 pmp in 2006 [AAPC 0.6% (95% CI 0.3-0.8%)]. This change in the trend of the incidence of RRT was largely due to a stabilization in the incidence rates of RRT for females aged 65-74 years, males aged 75-84 years and patients receiving RRT for ESRD due to hypertension/renal vascular disease. The overall adjusted prevalence in Europe continued to increase linearly at 2.7% per year. Between the periods 1997-2001 and 2002-2006, the risk of death decreased for all treatment modalities, with the most substantial improvement in patients starting peritoneal dialysis [19% (95% CI 15-22%)] and in patients receiving a kidney transplant [17% (95% CI 11-23%)].
Introduction
Since renal replacement therapy (RRT) for end-stage renal disease (ESRD) became widely available in the 1960s, the number of prevalent patients on RRT has continued to rise at an alarming rate. This has largely been due to an increased number of patients starting RRT and the improved survival of patients receiving dialysis or undergoing kidney transplantation [1] [2] [3] [4] . Two ERA-EDTA Registry publications [5, 6] based on relatively small databases earlier this decade outlined this almost linear increase of patient numbers as well as the substantial improvement in patient survival on RRT over time. However, more recent data seemed to indicate a stabilization in the incidence rates of RRT in a number of European countries [7] [8] [9] . The aim of this study was therefore to provide an update on the incidence, prevalence and outcomes of RRT for ESRD in Europe over the past decade in the 19 European countries and regions that currently provide individual patient data to the ERA-EDTA Registry.
Subjects and methods

Data collection
Nineteen national or regional renal registries participating in the ERA-EDTA Registry with individual patient data from 1 January 1997 to 31 December 2006 participated in the study. These included the national registries of Austria, Denmark, England/Wales [United Kingdom (UK)], Finland, Greece, Iceland, Norway, Scotland (UK), Sweden, The Netherlands and the regional registries of Dutch-and French-speaking Belgium, Calabria (covering 4% of Italy) and Andalusia, Asturias, Basque country, Cantabria, Catalonia and Valencian region (together covering 53% of Spain). The data from Asturias (Spain), Cantabria (Spain), Dutchspeaking Belgium, England/Wales (UK) and French-speaking Belgium only comprised patients >20 years of age. The population covered by these registries rose from 106 million people in 1997 to 157 million in 2006, which was partly due to the increasing coverage of the renal registry in the UK (from 25% in 1997 to 90% in 2006). Details of the database and the methods used for data collection and data processing have been previously reported [6] .
Data analysis
To avoid any effects of late reporting by renal centres over the period [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] , the recent 2007 update of the ERA-EDTA Registry database was used for analysis of the data.
The incidence of RRT was defined as the number of patients starting RRT annually and the prevalence as the number of patients alive and receiving RRT on 31 December. Incidence rates and prevalence per million population (pmp), or per million age-related population (pmarp) were calculated by dividing the observed count by the mid-year population. Primary renal diseases were defined according to the ERA-EDTA coding system and classified into seven groups [6, 10] . Adjusted rates were calculated by using the EU25 age and gender distribution [10] . Time trends were analysed with Poisson regression and Joinpoint regression. The slope of a trend was calculated using the observed rate as the outcome variable and the year as the explanatory variable. The analysis was adjusted for changes in the age and gender distribution of the population. The average annual percentage change (AAPC) was then computed by the formula AAPC = [exp(β)−1] × 100, where β denotes the regression coefficient representing the estimated effect of time on the rate. To examine whether trends were linear, Joinpoint regression software (version 3.3) provided by the Surveillance Research Program of the US National Cancer Institute [11] was used. Joinpoint regression allows the identification of points in time where a significant change in the linear slope of a trend occurs. The analysis starts with zero joinpoints (i.e. a straight line) and then tests whether one or more joinpoints are significantly different and must be added to the model [12] . The 10-year study period allowed identification of a maximum of two joinpoints.
Statistical analysis of unadjusted and adjusted survival was performed by the Kaplan-Meier method and by Cox proportional hazards regression. For the analysis of patient survival on RRT, the date of onset of RRT was the starting point and death was the event studied. Censored observations were recovery of renal function, loss to follow-up and end of the follow-up period. For analysis of patient survival on dialysis (overall and separately for haemodialysis and peritoneal dialysis) the first day on dialysis was the starting point, the event studied was death and reasons for censoring were recovery of renal function, loss to follow-up, end of follow-up time and kidney transplantation. For analysis of patient and graft survival after transplantation, the date of the first transplant was defined as the first day of follow-up. For the analysis of patient survival after transplantation, death was the event studied and for graft survival the events were graft failure and death. Reasons for censoring were loss to follow-up and end of the follow-up period. To study the trend in survival over time, the study patients were classified according to the date of the onset of RRT, the onset of dialysis or the date of the first kidney transplant into two cohorts: 1997-2001 and 2002-2006. SAS 9.1 software was used for all statistical analyses.
Results
Trends in the overall incidence rate of RRT, 1997 RRT, -2006 The unadjusted incidence rate of RRT for ESRD in the 19 countries/regions together increased from 107. 4 Figures 1 and 2 show the trends in the unadjusted incidence rates of RRT by gender and age group. For both males and females in the age groups 0-19 and 20-44 years and for males in the age group 45-64, the incidence rate of RRT remained unchanged during the study period, but among females in the age group 45-64 there was a slight decrease. In the age group 65-74 years, the incidence rate increased between 1997 and 2000 in both males and females (by 1.1 and 3.5%, respectively). However, after 2000 it stabilized in females, whereas it continued to increase in males. In the older age groups, there was a substantial increase in the incidence rates in both males and females during the early years of the decade, but the increase was much smaller towards the end of the period. Among males aged 75-84, the incidence rate of RRT even stabilized after 2004.
As shown in Figure 3 , the age-and gender-adjusted incidence rates of RRT for ESRD due to glomerulonephritis/sclerosis and pyelonephritis decreased during the study period, whereas that due to polycystic kidneys (adult type) remained stable. In 2004, after a long period of increase, the incidence rates of RRT for ESRD due to hypertension/renal vascular disease or miscellaneous causes started to stabilize, whereas those due to 'unknown/missing' causes continued to rise. In addition, the incidence of RRT for ESRD due to diabetes continued to increase after 2000, but at less than half the rate present before 2000. Subgroup analysis showed that the changes in the incidence rates of RRT for ESRD due to diabetes or hypertension/renal vascular disease were a consequence of changes of the incidence rates of RRT for ESRD due to these causes in patients aged 65-74 and 75-84 years. In addition, analysis of data from registries that used separate codes for nephropathy due to type 1 and type 2 diabetes showed that both increase in the incidence of RRT for diabetic ESRD and change in this trend, could be attributed to the age-and gender-adjusted Transplantation. In patients receiving their first kidney transplant both crude patient and graft survival improved (Table 3) . After adjustment for age, gender, primary renal disease and country, the risk of death in the 2002-2006 cohort was reduced by 17% and the risk of graft failure by 11%. This improvement was more pronounced in living donor transplants (30% for patient survival and 9% for graft survival) than in deceased donor transplants (13% for patient survival and 8% for graft survival). The trends in the 1-, 2-, 5-and 8-year survival of kidney transplant recipients and kidney allografts are shown in Figures 5 and 6 .
The pattern of improvement in survival was similar in all age, gender and primary renal disease groups.
Discussion
This European study shows a steady increase in the overall incidence of RRT for ESRD pmp during the period 1997-2000, followed by a much smaller increase of 0.6% per year thereafter. Although in some countries the prevalence of RRT stabilized in the more recent years, the overall prevalence in Europe continued to increase linearly at a rate of ∼2.7% per year. In addition, we show that the survival of patients on RRT improved between the periods 1997-2001 and 2002-2006. The risk of death decreased for all treatment modalities, with the most substantial improvement in survival observed in peritoneal dialysis patients (19%) and kidney transplant recipients (17%) and a more moderate improvement in haemodialysis patients (10%).
After a steady rise in the overall incidence rate of RRT for ESRD in Europe, from 50 pmp in 1980 to 117 pmp in 1998-1999 [1, 5] , our results demonstrated a further increase to 125.4 pmp in 2006. However, starting from 2000, there was a trend towards stabilization of the overall incidence rate, with an average annual increase of only 0.6%, albeit substantial differences existed between countries and regions in Europe. This is consistent with trends in the United States [13, 14] , New Zealand [15, 16] and Canada [17] , where registry data also show a less steep increase in the more recent years.
The increase of the (unadjusted) overall incidence rate of RRT between 1997 and 2000 was primarily due to increasing rates in the three oldest age groups, 65-74 years, 75-84 years and 85 years and older. There appears to be a relationship between the age at the onset of RRT and the period in which the stabilization of incidence rates occurred. Whereas the incidence rate in the age groups <45 years has been stable for decades [5] , that in the 45-64 age group became stable at the end of the 1990s [18] . The results of this study show that in males aged 65-74 years, the incidence rate of RRT increased by only 1.1% annually, whereas it levelled of in females. Remarkably, also in males aged 75-84 years, rates have stabilized from 2004, and in females the AAPC decreased to 1.8% per year [5, 19] . Nevertheless, the incidence rate among those aged 85 years and older continued to rise although this rise was much smaller towards the end of the study period. In line with our results, other large registries [13, [15] [16] [17] have also found that the rate of increase in incidence among patients aged 65-74 and 75 years and older was much lower after 2000 than before. Australia are trends lacking stabilization in the older age groups lacking.
Similar trends towards stabilization were found in the incidence rates of RRT for ESRD due to hypertension/renal vascular disease (stable from 2004) and type 2 diabetes (a less steep increase starting from 2002), respectively, which appears to result primarily from the stabilizing incidence rates of RRT for ESRD due to these primary renal diseases in the age groups 65-74 and 75-84 years. However, at the same time, the incidence rate of RRT for ESRD due to unknown or missing causes increased, and therefore, our findings concerning the different primary renal disease categories should be interpreted with caution. Nevertheless, similar results were found by Foley et al. [14] who demonstrated that among whites aged 60-69 years in the United States, the incidence rate of RRT for ESRD due to diabetes remained constant after 2000. Furthermore, these data suggested a flattening of the growth of the incidence of RRT for ESRD due to hypertension.
The recent decline in the annual growth of the incidence rate of RRT for ESRD in Europe could be explained by several factors: a stabilization in the prevalence of underlying causes of ESRD, a slower progression of chronic kidney disease (CKD) to ESRD, as well as a higher mortality in the earlier stages of CKD. Despite a steady increase in the prevalence of diabetes [20] and hypertension [21] in the general population, our data showed a flattening of the incidence rates of RRT for ESRD due to these disorders within the older age groups. It has been suggested that this could be due to the increasing awareness of the growing burden of CKD [22] [23] [24] [25] and the greater emphasis on early detection and prevention. Therapeutic interventions now available aim to reduce the rate of progression of CKD [22, 26] and the extent of comorbid conditions and complications. Perhaps these primary and secondary prevention methods are now starting to bear fruit resulting in incidence rates of RRT that are increasing at a much lower pace.
Previous studies have shown that a considerable proportion of patients with CKD die before reaching ESRD [27] [28] [29] ; however, there are no indications for increasing death rates in CKD patients [13] that could explain the stabilizing incidence rates of RRT. Another potential cause of a slower rise in the incidence is reduced access to RRT due to non-referral or late referral to nephrologists. However, this seems to be unlikely, as the incidence rate in the group that would be most likely be affected, i.e. the patients aged 85 years and older, has continued to increase.
On the other hand, a small but continuous increase in the incidence rate of RRT could be caused by a tendency towards starting dialysis earlier in the course of CKD, i.e. at higher levels of residual renal function [30, 31] . In this perspective, it is of interest to note that USRDS data showed that almost the entire increase in the incidence counts during the period 1996-2005 occurred in patients who started RRT at higher levels of estimated glomerular filtration rate (>10 ml/min/1.73 m 2 ) [32] . All medical (e.g. prevalence of diabetes mellitus in the general population) and non-medical factors (e.g. nonreferral to nephrologists) that influence the trends in the incidence rate of RRT may also explain international differences in the incidence rate trends.
We show that although the crude survival on RRT did not improve substantially, the adjusted survival of patients on dialysis and after transplantation, as well as graft survival after transplantation continued to improve during the last decade. Especially the patient survival on peritoneal dialysis has improved. This might be due to the more widespread use of biocompatible solutions, icodextrin and optimization of the length of the short dwell using automated peritoneal dialysis together resulting in a better preservation of the peritoneal membrane, a better preservation of the residual renal function and a better control of fluid balance, especially in high transporters [33] [34] [35] [36] [37] [38] [39] [40] [41] . In addition, another selection of patients for this mode of treatment might have contributed to the improved patient survival on peritoneal dialysis. The survival after kidney transplantation has improved substantially, presumably partly due to slight increases in percentages of living donor kidney transplants and pre-emptive transplants, and also due to increased tailoring of immune suppression to the individual patient and avoidance of excessive toxic drug use [42, 43] . The improvement in the survival on RRT might also be a consequence of the primary and secondary prevention methods leading to a better condition of patients starting RRT [44] (less complications) and more adequate medical and psychological preparations for RRT [45, 46] .
Conclusions
This European study shows that on average there is a decrease in the annual growth of the overall incidence rate of RRT for ESRD and a trend towards stabilization. This is largely due to a stabilization of the incidence among females aged 65-74 years, males aged 75-84 years and in patients receiving RRT for ESRD due to hypertension/renal vascular disease. Nevertheless, trends in the incidence rates of RRT differed widely across countries, ranging from steady increase to substantial decrease, potentially due to differences in the prevalence and progression of CKD and variable access to RRT. Therefore, international research in CKD patients using standardized methodology is necessary.
The survival of patients on dialysis, and even more after kidney transplantation continued to improve between the periods 1997-2001 and 2002-2006. This might not only be due to technical improvements in RRT, but also to a better condition of patients starting RRT due to increased awareness of the importance to detect and treat patients with CKD to delay its progression.
Our data suggest that nephrologists in Europe are making progress in their efforts to prevent the development of ESRD and to prolong the survival of those who, in spite of these efforts, will require RRT. These findings should stimulate further action to control the progression of CKD by implementation of effective renoprotective strategies.
Introduction
The first two cases of influenza A(H1N1)v were identified in two southern California counties on 15 and 17 April 2009. Since that time cases have been documented throughout the world, initially with most of them occurring not only in the United States but also in Mexico, where influenza A/H1N1)v was later proved to have originated in March 2009. The World Health Organization declared a pandemic on 11 June 2009. On the basis of the surveillance measures put in place by several Healthcare Authorities, the first wave of the pandemic is now ending in many countries, with a progressive decrease in the number of new cases reported [1] . Accurate statistics are not available, but it can be assumed that the first wave of influenza affected a low proportion of the population of the countries involved. History suggests that a second, larger wave of flu is to be expected; however, the timing and severity of a second wave
